Apoptosis Assays Market

The report "Apoptosis Assays Market by Product (Caspase, Annexin V, DNA Fragmentation, Mitochondrial Assay), Detection Technology (Flow Cytometry, Florescence microscopy), Application (Stem Cell, Discovery & Development, Clinical Research) - Global Forecast to 2023", The apoptosis assays market is expected to reach USD 5.9 billion by 2023 from an estimated USD 3.6 billion in 2018, at a CAGR of 10.5%. The major factors driving the growth of this market include the rising incidence and prevalence of chronic and infectious diseases, growing funding for cancer research, growing cell-based research, and development of apoptosis-modulating drugs.

Browse 125 market data Tables and 37 Figures spread through 206 Pages and in-depth TOC on "Apoptosis Assays Market by Product (Caspase, Annexin V, DNA Fragmentation, Mitochondrial Assay), Detection Technology (Flow Cytometry, Florescence microscopy), Application (Stem Cell, Discovery & Development, Clinical Research) - Global Forecast to 2023"
View detailed Table of Content here - https://www.marketsandmarkets.com/Market-Reports/apoptosis-assays-market-9069428.html

By product, the Assay kits segment is expected to account for the largest share of the apoptosis assays market in 2018

On the basis of product, assay kits segment is expected to account for the largest share of the apoptosis assays market in 2018. Assay kits are widely used in life sciences research, drug discovery and development, and environmental monitoring in a broad range of applications such as studying disease pathways, screening for potential drug candidates, and evaluating biopharmaceutical production processes. This large share can be attributed to the repeated consumption of assay kits as consumables in various apoptosis testing processes.

By application, the drug discovery & development application segment is projected to have the largest market share during the forecast period (2018-2023)”

Based on application, the apoptosis assays market is segmented into drug discovery & development, clinical & diagnostic applications, basic research, and stem cell research. In 2018, the drug discovery & development application segment is expected to account for the largest share of the global apoptosis assays market. The large share of this segment can be attributed to the rising incidence and prevalence of chronic and infectious diseases and increasing government support for developing new treatments for various human diseases.

By end user, the pharmaceutical and biotechnology companies segment is is projected to have the largest market share during the forecast period (2018-2023)”

On the basis of end user, the apoptosis assays market is segmented into pharmaceutical and biotechnology companies, hospital and diagnostic laboratories, and academic and research institutes. The pharmaceutical and biotechnology companies segment is expected to account for the largest share in 2018. The large share of this segment can be attributed to the increasing number of R&D activities undertaken by these companies for the development of biopharmaceutical products.

North America to dominate the market in 2018

North America is expected to account for the largest share of the apoptosis assays market in 2018, followed by Europe and Asia Pacific. The rising incidence and prevalence of chronic and infectious diseases, a large number of life science research studies conducted in the region, favorable government support in the form of research investments, and presence of high-quality infrastructure for clinical and laboratory research are the major factors responsible for the large share of the North American apoptosis assays market.

The prominent players in the apoptosis assays market are Merck KGaA (Germany), Thermo Fisher Scientific (US), Bio-Rad Laboratories (US), Becton, Dickinson and Company (US), GE Healthcare (US), Sartorius AG (Germany), Danaher Corporation (US), Geno Technology (US), GeneCopoeia, Inc. (US), Bio-Techne Corporation(US), BioTek Instruments (US), PerkinElmer (US), Promega Corporation (US), Biotium (US), Abcam plc (UK), Canvax (Spain), Abnova (Taiwan), and Creative Bioarray (US).

About MarketsandMarkets™

MarketsandMarkets™ provides quantified B2B research on 30,000 high growth niche opportunities/threats which will impact 70% to 80% of worldwide companies’ revenues. Currently servicing 7500 customers worldwide including 80% of global Fortune 1000 companies as clients. Almost 75,000 top officers across eight industries worldwide approach MarketsandMarkets™ for their painpoints around revenues decisions.

Our 850 fulltime analyst and SMEs at MarketsandMarkets™ are tracking global high growth markets following the "Growth Engagement Model – GEM". The GEM aims at proactive collaboration with the clients to identify new opportunities, identify most important customers, write "Attack, avoid and defend" strategies, identify sources of incremental revenues for both the company and its competitors. MarketsandMarkets™ now coming up with 1,500 MicroQuadrants (Positioning top players across leaders, emerging companies, innovators, strategic players) annually in high growth emerging segments. MarketsandMarkets™ is determined to benefit more than 10,000 companies this year for their revenue planning and help them take their innovations/disruptions early to the market by providing them research ahead of the curve.

MarketsandMarkets’s flagship competitive intelligence and market research platform, "Knowledgestore" connects over 200,000 markets and entire value chains for deeper understanding of the unmet insights along with market sizing and forecasts of niche markets.

Contact:
Mr. Shelly Singh
MarketsandMarkets™ INC.
630 Dundee Road
Suite 430
Northbrook, IL 60062
USA : 1-888-600-6441
[email protected]